1.49
price up icon6.43%   0.09
after-market 시간 외 거래: 1.52 0.03 +2.01%
loading
전일 마감가:
$1.40
열려 있는:
$1.44
하루 거래량:
3.03M
Relative Volume:
1.10
시가총액:
$106.11M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-1.9867
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
+14.62%
1개월 성능:
-8.59%
6개월 성능:
+422.26%
1년 성능:
+41.90%
1일 변동 폭
Value
$1.42
$1.555
1주일 범위
Value
$1.21
$1.555
52주 변동 폭
Value
$0.2425
$2.01

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name
명칭
Ovid Therapeutics Inc
Name
전화
212-776-4381
Name
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Name
직원
23
Name
트위터
@OvidRx
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
OVID's Discussions on Twitter

OVID을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
OVID
Ovid Therapeutics Inc
1.49 99.70M 391.70K -52.34M -45.92M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.00 108.28B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
761.45 79.44B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.23 57.65B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
906.74 56.58B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
206.93 42.39B 447.02M -1.18B -906.14M -6.1812

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-11-17 개시 Leerink Partners Outperform
2025-10-09 개시 Oppenheimer Outperform
2025-08-08 재개 B. Riley Securities Buy
2024-06-18 다운그레이드 Oppenheimer Outperform → Perform
2024-04-30 개시 B. Riley Securities Buy
2024-04-29 개시 H.C. Wainwright Buy
2024-04-05 개시 Wedbush Outperform
2023-12-21 개시 BTIG Research Buy
2023-10-13 개시 Oppenheimer Outperform
2021-04-20 다운그레이드 Cantor Fitzgerald Buy → Neutral
2021-03-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-12-02 다운그레이드 Citigroup Buy → Neutral
2020-12-02 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2019-09-04 개시 RBC Capital Mkts Outperform
2018-04-20 개시 Ladenburg Thalmann Buy
모두보기

Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스

pulisher
07:40 AM

Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus

07:40 AM
pulisher
Nov 21, 2025

Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights

Nov 21, 2025
pulisher
Nov 21, 2025

Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Ovid Therapeutics Reports Q3 2025 Financial Results - MSN

Nov 19, 2025
pulisher
Nov 19, 2025

Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Historical volatility pattern of Ovid Therapeutics Inc. visualizedWeekly Investment Summary & Free High Accuracy Swing Entry Alerts - newser.com

Nov 19, 2025
pulisher
Nov 17, 2025

Leerink Partners Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq

Nov 17, 2025
pulisher
Nov 17, 2025

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Nov 17, 2025
pulisher
Nov 17, 2025

OVID: Leerink Partners Initiates Coverage with 'Outperform' Rati - GuruFocus

Nov 17, 2025
pulisher
Nov 17, 2025

Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target - MarketScreener

Nov 17, 2025
pulisher
Nov 17, 2025

Can trapped investors hope for a rebound in Ovid Therapeutics Inc.2025 Market Sentiment & Daily Stock Trend Reports - newser.com

Nov 17, 2025
pulisher
Nov 17, 2025

Ovid Therapeutics (OVID) Receives Positive Outlook from Analyst - GuruFocus

Nov 17, 2025
pulisher
Nov 17, 2025

How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsMarket Activity Report & Consistent Profit Trading Strategies - newser.com

Nov 17, 2025
pulisher
Nov 16, 2025

Published on: 2025-11-16 07:02:40 - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

Price to book ratio of Ovid Therapeutics Inc. – HAM:1OT - TradingView

Nov 15, 2025
pulisher
Nov 14, 2025

Published on: 2025-11-14 21:11:45 - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Is Ovid Therapeutics Inc. (1OT) stock protected from inflationWeekly Profit Summary & Real-Time Buy Signal Notifications - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Is Ovid Therapeutics Inc. stock oversold or undervaluedPortfolio Update Report & Community Driven Trade Alerts - Fundação Cultural do Pará

Nov 14, 2025
pulisher
Nov 13, 2025

Ovid Therapeutics Draws Strong Buy Ratings After Q3 Earnings Update - Finimize

Nov 13, 2025

Ovid Therapeutics Inc (OVID) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$39.75
price up icon 2.13%
$30.82
price up icon 1.22%
$106.24
price up icon 4.10%
$96.54
price up icon 0.99%
biotechnology ONC
$332.71
price down icon 4.32%
$206.93
price up icon 4.11%
자본화:     |  볼륨(24시간):